Cargando…

Melanoma patterns of distant relapse: a study of 108 cases from a South Brazilian center

BACKGROUND: The incidence of cutaneous melanoma has increased over the last decades. Recurrences occur most frequently within the first 2-3 years after diagnosis but patients carry a lifelong risk of relapse. Nevertheless, there is no consensus in the literature on what screening tests patients shou...

Descripción completa

Detalles Bibliográficos
Autores principales: Rovere, Rodrigo Kraft, de Souza, Maria Eduarda Pires, Cidral, Danielle Louise da Maia, Hilgert, Sara Fernanda, Ddine, Yasmine Rodrigues Chamse, Stein, Carlos Efrain, Borges, Giuliano Santos, de Lima, Adma Silva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782645/
https://www.ncbi.nlm.nih.gov/pubmed/26982777
http://dx.doi.org/10.1590/abd1806-4841.20163722
Descripción
Sumario:BACKGROUND: The incidence of cutaneous melanoma has increased over the last decades. Recurrences occur most frequently within the first 2-3 years after diagnosis but patients carry a lifelong risk of relapse. Nevertheless, there is no consensus in the literature on what screening tests patients should undergo. OBJECTIVES: To evaluate the most common melanoma metastasis sites among a South Brazilian population from a city with one of the highest melanoma rates, and establish the best screening method for these patients. METHODS: A cross-sectional retrospective study of 108 consecutive melanoma patients followed up at a center from 2009 to 2013. Data were collected on demographic and tumoral characteristics, as well as the site of the first diagnosed metastasis. RESULTS: Patients were divided into 3 groups for analytical purposes: Non-visceral metastases (48% of patients), visceral metastasis (39%) and brain metastasis (13%). We tried to correlate age, gender, mean Breslow thickness, mitosis and death rates with the aforementioned groups but none showed any statistically significant association. CONCLUSION: Melanoma patients must be monitored to detect early relapse and subsequent effective treatment but the best follow-up strategy remains to be established.